The Talazoparib Beyond BRCA phase 2 study demonstrated the efficacy of Talazoparib, a PARPi, in advanced breast cancer with germline PALB2 PV/LPV, showing activity within the context of HRD beyond BRCA1/2 [103]. This evidence concerns the gene BRCA1 and breast cancer.